185 related articles for article (PubMed ID: 35177777)
1. A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia.
Yasara N; Wickramarathne N; Mettananda C; Silva I; Hameed N; Attanayaka K; Rodrigo R; Wickramasinghe N; Perera L; Manamperi A; Premawardhena A; Mettananda S
Sci Rep; 2022 Feb; 12(1):2752. PubMed ID: 35177777
[TBL] [Abstract][Full Text] [Related]
2. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial.
Yasara N; Wickramarathne N; Mettananda C; Manamperi A; Premawardhena A; Mettananda S
BMJ Open; 2020 Oct; 10(10):e041958. PubMed ID: 33109679
[TBL] [Abstract][Full Text] [Related]
4. Alpha Globin Gene Mutation: A Major Determinant of Hydroxyurea Response in Transfusion-Dependent HbE-β-Thalassaemia.
Biswas S; Ray R; Roy K; Bandyopadhyay A; Ghosh K; Bhattacharyya M
Acta Haematol; 2019; 142(3):132-141. PubMed ID: 31352439
[TBL] [Abstract][Full Text] [Related]
5. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.
Foong WC; Ho JJ; Loh CK; Viprakasit V
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD011579. PubMed ID: 27755646
[TBL] [Abstract][Full Text] [Related]
7. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
Fucharoen S; Inati A; Siritanaratku N; Thein SL; Wargin WC; Koussa S; Taher A; Chaneim N; Boosalis M; Berenson R; Perrine SP
Br J Haematol; 2013 May; 161(4):587-93. PubMed ID: 23530969
[TBL] [Abstract][Full Text] [Related]
9. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia.
Saxon BR; Rees D; Olivieri NF
Br J Haematol; 1998 Jun; 101(3):416-9. PubMed ID: 9633880
[TBL] [Abstract][Full Text] [Related]
10. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
[No Abstract] [Full Text] [Related]
11. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome.
Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP;
Br J Haematol; 2005 Nov; 131(3):378-88. PubMed ID: 16225658
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.
Yasara N; Premawardhena A; Mettananda S
Orphanet J Rare Dis; 2021 Mar; 16(1):114. PubMed ID: 33648529
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India.
Chatterjee T; Chakravarty A; Chakravarty S
Ann Hematol; 2018 May; 97(5):893-898. PubMed ID: 29453624
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.
Ansari SH; Lassi ZS; Khowaja SM; Adil SO; Shamsi TS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012064. PubMed ID: 30882896
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients.
Watanapokasin Y; Chuncharunee S; Sanmund D; Kongnium W; Winichagoon P; Rodgers GP; Fucharoen S
Exp Hematol; 2005 Dec; 33(12):1486-92. PubMed ID: 16338491
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.
Pourfarzad F; von Lindern M; Azarkeivan A; Hou J; Kia SK; Esteghamat F; van Ijcken W; Philipsen S; Najmabadi H; Grosveld F
Haematologica; 2013 May; 98(5):696-704. PubMed ID: 23100274
[TBL] [Abstract][Full Text] [Related]
18. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients.
Chondrou V; Kolovos P; Sgourou A; Kourakli A; Pavlidaki A; Kastrinou V; John A; Symeonidis A; Ali BR; Papachatzopoulou A; Katsila T; Patrinos GP
Hum Genomics; 2017 Oct; 11(1):24. PubMed ID: 29061162
[TBL] [Abstract][Full Text] [Related]
19. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.
Ansari SH; Shamsi TS; Munzir S; Khan MT; Erum S; Perveen K; Farzana T; Ashraf M; Mehboob T; Moinuddin M
J Pediatr Hematol Oncol; 2013 May; 35(4):e153-6. PubMed ID: 23389500
[TBL] [Abstract][Full Text] [Related]
20. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients.
Rigano P; Pecoraro A; Calzolari R; Troia A; Acuto S; Renda D; Pantalone GR; Maggio A; Di Marzo R
Br J Haematol; 2010 Dec; 151(5):509-15. PubMed ID: 20955403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
